Verve Therapeutics

General Information

We are a genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. Despite advances in treatment over the last 50 years, CVD remains the leading cause of death worldwide. The current paradigm of chronic care is fragile—requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access—and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. Our initial two programs target PCSK9 and ANGPTL3, respectively, genes that have been extensively validated as targets for lowering blood lipids, such as low-density lipoprotein cholesterol, or LDL-C. We believe that editing these genes could potently and durably lower LDL-C throughout the lifetime of patients with or at risk for atherosclerotic cardiovascular disease, or ASCVD, the most common form of CVD.

(Note: Verve Therapeutics priced its IPO on June 16, 2021, at $19 – above its $16-to-$18 range – on 14.04 million shares – an increase from the 11.8 million shares in the prospectus – to raise $266.7 million.)

Employees: 70
Founded: 2018
Contact Information
Address 500 Technology Square, Suite 901, Cambridge, Massachusetts 02139, US
Phone Number (617) 603-0070
Web Address
View Prospectus: Verve Therapeutics
Financial Information
Market Cap $876.1mil
Revenues $0 mil (last 12 months)
Net Income $-7.66 mil (last 12 months)
IPO Profile
Symbol VERV
Exchange NASDAQ
Shares (millions): 14.0
Price range $19.00 - $19.00
Est. $ Volume $266.7 mil
Manager / Joint Managers J.P. Morgan/ Jefferies/ Guggenheim Securities/ William Blair
Expected To Trade: 6/17/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change